Mechanistically, MEG3 promotes osteosarcoma chemosensitivity by regulating anti-tumor immunity through the miR-21-5p/p53 pathway and autophagy, demonstrating that MEG3 may be a promising therapeutic target for osteosarcoma chemoresistance (86). Here, MEG3 is linked to neoplasm.